Menu Search
Equities

Molecure SA

1B1:STU

Molecure SA

Actions
  • Price (EUR)2.91
  • Today's Change-0.08 / -2.68%
  • Shares traded0.00
  • 1 Year change-26.08%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Molecure SA's revenues fell -18.85% from 1.61m to 1.31m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 15.30m to a larger loss of 18.31m.
Gross margin-444.01%
Net profit margin-6,082.40%
Operating margin-6,902.23%
Return on assets-18.17%
Return on equity-20.16%
Return on investment-19.29%
More ▼

Cash flow in PLNView more

In 2023, Molecure SA did not generate a significant amount of cash. Cash Flow from Financing totalled 54.74m or 4,182.92% of revenues. In addition the company used 11.60m for operations while cash used for investing totalled 44.76m.
Cash flow per share-1.24
Price/Cash flow per share--
Book value per share5.59
Tangible book value per share2.95
More ▼

Balance sheet in PLNView more

Molecure SA appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.27% of the market capitalization can be attributed to its 63.99m and debt could be paid in full if management chose.
Current ratio5.79
Quick ratio--
Total debt/total equity0.0703
Total debt/total capital0.0657
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.